Cohort study on the treatment of BRAF V600E mutant metastatic colorectal cancer with integrated Chinese and western medicine

Table 2 Subgroup analysis

Subgroup	mOS (month)		χ2	P value	HR (95%CI)
	Cohort A	Cohort B
Right-side colon	25.5	10.15	6.335	0.012	0.25 (0.07, 0.83)
Liver metastasis	21	8.1	7.192	0.007	0.22 (0.06, 1.80)
Targeted therapy	26	13.2	3.918	0.073	0.40 (0.14, 1.20)
Chemotherapy	21	14.2	5.475	0.019	0.38 (0.17, 0.90)
First-line treatment	21	13.2	8.597	0.003	0.25 (0.09, 0.67)

mOS: Median overall survival.